Literature DB >> 12225947

Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation.

Yong D Li1, Edward R Block, Jawaharlal M Patel.   

Abstract

Signaling events involving angiotensin IV (ANG IV)-mediated pulmonary artery endothelial cell (PAEC) proliferation were examined. ANG IV significantly increased upstream phosphatidylinositide (PI) 3-kinase (PI3K), PI-dependent kinase-1 (PDK-1), extracellular signal-related kinases (ERK1/2), and protein kinase B-alpha/Akt (PKB-alpha) activities, as well as downstream p70 ribosomal S6 kinase (p70S6K) activities and/or phosphorylation of these proteins. ANG IV also significantly increased 5-bromo-2'-deoxy-uridine incorporation into newly synthesized DNA in a concentration- and time-dependent manner. Pretreatment of cells with wortmannin and LY-294002, inhibitors of PI3K, or rapamycin, an inhibitor of the mammalian target of rapamycin kinase and p70S6K, diminished the ANG IV-mediated activation of PDK-1 and PKB-alpha as well as phosphorylation of p70S6K. Although an inhibitor of mitogen-activated protein kinase kinase, PD-98059, but not rapamycin, blocked ANG IV-induced phosphorylation of ERK1/2, both PD-98059 and rapamycin independently caused partial reduction in ANG IV-mediated cell proliferation. However, simultaneous treatment with PD-98059 and rapamycin resulted in total inhibition of ANG IV-induced cell proliferation. These results demonstrate that ANG IV-induced DNA synthesis is regulated in a coordinated fashion involving multiple signaling modules in PAEC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225947     DOI: 10.1152/ajplung.00024.2002

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  17 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

3.  Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells.

Authors:  Jianghua Lu; Jianalian Zhang; Edward R Block; Jawaharlal M Patel
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

4.  The effects of angiotensin peptides and angiotensin receptor antagonists on the cell growth and angiogenic activity of GH3 lactosomatotroph cells in vitro.

Authors:  Dorota Ptasinska-Wnuk; Slawomir A Mucha; Hanna Lawnicka; Jolanta Fryczak; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Endocrine       Date:  2012-03-23       Impact factor: 3.633

5.  Angiotensin IV upregulates the activity of protein phosphatase 1α in Neura-2A cells.

Authors:  Dan Wang; Peng Xue; Xiu Lan Chen; Zhen Sheng Xie; Fu Quan Yang; Li Zheng; Tao Xu
Journal:  Protein Cell       Date:  2013-06-06       Impact factor: 14.870

6.  Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity.

Authors:  Hanbo Hu; Sergey Zharikov; Jawaharlal M Patel
Journal:  Peptides       Date:  2012-03-20       Impact factor: 3.750

Review 7.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

8.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

Review 9.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

10.  Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension.

Authors:  Aiko Ogawa; Amy L Firth; Weijuan Yao; Michael M Madani; Kim M Kerr; William R Auger; Stuart W Jamieson; Patricia A Thistlethwaite; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-24       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.